Bivalirudin is a new synthetic anticoagulant drug. It is a direct, specific and reversible inhibitor of thrombin. Originally developed by Biogen, Switzerland, it was transferred to the American medicines company and approved to be listed in the United States in 2000. Its anticoagulant component is a 20 peptide compound derived from hirudin. Whether thrombin in blood circulation or thrombin bound to thrombus, bivalirudin can specifically bind to its catalytic site and anion binding site, so as to directly inhibit the activity of thrombin, and its action is short-lived and reversible. Early clinical studies have shown that bivalirudin anticoagulant therapy is effective, and the incidence of bleeding events is low, which is safer than traditional heparin anticoagulant therapy. It is mainly used to prevent ischemic complications before and after angioplasty and interventional treatment of unstable angina pectoris.